About us

Pichia pastoris protein expression excellence

VALIDOGEN, founded in 2008 as VTU Technology GmbH and renamed VALIDOGEN GmbH in October 2018, is a leading contract research and development organization (CRO) specializing in recombinant protein expression using its exclusive UNLOCK PICHIA® protein expression technology.

With its UNLOCK PICHIA® platform, VALIDOGEN applies a broad and unique portfolio of technologies for successful and economically viable production of recombinant proteins in the yeast Pichia pastoris (also known as as Komagataella phaffii), serving many industries including biopharma, food & feed, industrial biotechnology, and diagnostics. 

VALIDOGEN provides advanced Pichia strain generation as well as fermentation and protein purification process development for the manufacture of biopharmaceuticals, enzymes, and other recombinant proteins. Based on our strong Pichia expertise, customers from different industries have successfully scaled up commercial production processes with highly effective Pichia strains for the production of recombinant proteins for pharma and non-pharma applications.  

Headquartered in Raaba-Grambach, near Graz, Austria, VALIDOGEN is a private company and subsidiary of KonValue Holding GmbH.

Track Record

Contract Research Projects
  • Serving customers for more than 15 years
  • High-performance strains and processes developed for numerous industries and applications
  • Projects with clients ranging from small start-ups to industry giants
Tech Transfer & Scale up
  • Efficient process transfer & scale-up to industrial scale (up to 100,000 L)
  • Phase I & II clinical studies performed with proteins produced using UNLOCK PICHIA®
  • Proteins produced by UNLOCK PICHIA® technologies on the market in different industry sectors
Intellectual Property
  • Firm IP position
  • Strengthening our technological leadership position
  • Continued R&D development generating new expertise and IP


Roland Weis, PhD
Head of Operations & CEO
Thomas Purkarthofer, PhD
Head Business Development & CEO
Michael Koncar, PhD
Founder & CEO